Reproductive endocrinology: Postmenopausal hormone therapy: Risks versus benefits reassessed

Nature Reviews Endocrinology

Volumn 6, Issue 12, 2010, Pages 661-663

  Simon, James A ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO; RALOXIFENE;

BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; TREATMENT PLANNING; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; METHODOLOGY; PERCEPTION; PHYSICIAN; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PERCEPTION; PHYSICIANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 78649440379     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.191     Document Type: Short Survey

References (10)

1. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's Health initiative randomized controlled trial. JAMA 288, 321-333 (2002).
2. Santen, R. J. et al. Postmenopausal hormone therapy: an endocrine society scientific statement. J. Clin. Endocrinol. Metab. 95 (suppl. 1), s1-s66 (2010).
3. Pilon, D., Castilloux, A. M. & LeLorier, J. estrogen replacement therapy: determinants of persistence with treatment. Obstet. Gynecol. 97, 97-100 (2001).
4. Santen, R. J. & Allred, D. C. The estrogen paradox. Nat. Clin. Pract. Endocrinol. Metab. 3, 496-497 (2007).
5. Barrett-Connor, e. et al. effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137 (2006). (Pubitemid 44050394)
6. Ellis, M. J. et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 302, 774-780 (2009).
7. Simon, J. A. Postmenopausal estrogen therapy: which route to take? Nat. Clin. Pract. Endocrinol. Metab. 5, 146-147 (2009).
8. Simon, J. A., nahum, G. G., stanislaw, H. & Gaines, T. The breast cancer "plunge" after initial publication of the WHi results: an alternative explanation. Maturitas 66, 277-284 (2010).
9. Hodis, H. N. Assessing benefits and risks of hormone therapy in new evidence, especially with regard to the heart. Cleve. Clin. J. Med. 75 (Suppl. 4), s3-s12 (2008).
10. Galloway, V. A. & Brodsky, S. L. Caring less, doing more: the role of therapeutic detachment with volatile and unmotivated clients. Am. J. Psychother. 57, 32-38 (2003).